Dupont Capital Management Corp increased its stake in Danaher Corporation (NYSE:DHR) by 27.1% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 38,041 shares of the conglomerate’s stock after purchasing an additional 8,118 shares during the period. Dupont Capital Management Corp’s holdings in Danaher Corporation were worth $3,210,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in DHR. Peddock Capital Advisors LLC lifted its position in Danaher Corporation by 17.4% during the 1st quarter. Peddock Capital Advisors LLC now owns 1,224 shares of the conglomerate’s stock worth $105,000 after buying an additional 181 shares in the last quarter. Proficio Capital Partners LLC lifted its position in Danaher Corporation by 92.3% during the 1st quarter. Proficio Capital Partners LLC now owns 1,246 shares of the conglomerate’s stock worth $105,000 after buying an additional 598 shares in the last quarter. ClariVest Asset Management LLC bought a new stake in Danaher Corporation during the 1st quarter worth about $157,000. Cornerstone Advisors Inc. lifted its position in Danaher Corporation by 62.0% during the 2nd quarter. Cornerstone Advisors Inc. now owns 2,111 shares of the conglomerate’s stock worth $178,000 after buying an additional 808 shares in the last quarter. Finally, Baystate Wealth Management LLC lifted its position in Danaher Corporation by 11.3% during the 2nd quarter. Baystate Wealth Management LLC now owns 2,115 shares of the conglomerate’s stock worth $181,000 after buying an additional 215 shares in the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This report was published by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.watchlistnews.com/danaher-corporation-dhr-shares-bought-by-dupont-capital-management-corp/1579317.html.

In other Danaher Corporation news, insider Thomas Patrick Joyce, Jr. sold 9,772 shares of Danaher Corporation stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $81.78, for a total value of $799,154.16. Following the sale, the insider now owns 155,520 shares of the company’s stock, valued at $12,718,425.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider William King sold 7,458 shares of Danaher Corporation stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $82.97, for a total transaction of $618,790.26. Following the completion of the sale, the insider now directly owns 18,245 shares in the company, valued at approximately $1,513,787.65. The disclosure for this sale can be found here. In the last ninety days, insiders sold 71,496 shares of company stock worth $5,916,223. Insiders own 12.20% of the company’s stock.

Several equities research analysts have commented on DHR shares. Zacks Investment Research cut shares of Danaher Corporation from a “hold” rating to a “sell” rating in a research report on Monday, June 19th. Deutsche Bank AG reissued a “buy” rating and set a $97.00 price target on shares of Danaher Corporation in a research report on Wednesday, June 21st. Wells Fargo & Company started coverage on shares of Danaher Corporation in a research report on Thursday, July 13th. They set a “market perform” rating and a $90.00 price target on the stock. BidaskClub cut shares of Danaher Corporation from a “hold” rating to a “sell” rating in a research report on Saturday, July 8th. Finally, Jefferies Group LLC reissued a “buy” rating and set a $95.00 price target on shares of Danaher Corporation in a research report on Friday, August 4th. One research analyst has rated the stock with a sell rating, three have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $92.72.

Shares of Danaher Corporation (DHR) opened at 86.42 on Friday. The stock has a 50 day moving average of $82.99 and a 200-day moving average of $84.20. Danaher Corporation has a one year low of $75.71 and a one year high of $88.62. The company has a market capitalization of $60.04 billion, a PE ratio of 27.58 and a beta of 1.03.

Danaher Corporation (NYSE:DHR) last released its quarterly earnings results on Thursday, July 20th. The conglomerate reported $0.99 earnings per share for the quarter, topping the consensus estimate of $0.97 by $0.02. Danaher Corporation had a net margin of 12.63% and a return on equity of 11.15%. The business had revenue of $4.51 billion for the quarter, compared to analysts’ expectations of $4.50 billion. During the same period in the previous year, the company earned $0.90 earnings per share. The firm’s revenue for the quarter was up 6.3% compared to the same quarter last year. On average, equities analysts forecast that Danaher Corporation will post $3.95 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Shareholders of record on Friday, September 29th will be given a $0.14 dividend. This represents a $0.56 annualized dividend and a yield of 0.65%. The ex-dividend date of this dividend is Thursday, September 28th. Danaher Corporation’s dividend payout ratio is 17.83%.

Danaher Corporation Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Institutional Ownership by Quarter for Danaher Corporation (NYSE:DHR)

Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.